Ichnos Glenmark Innovation
Blood & Organ Banks · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 World Trade Ctr Fl 76 Ste D, New York ...Website
www.iginnovate.comRevenue
<$5 MillionIndustry
ZI Rank: 4
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
2
2
5
3
4
About Ichnos Glenmark Innovation
IGI, Inc. is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors.Explore more
Popular SearchesIchnos Glenmark InnovationSIC Code 28,283NAICS Code 32,325Show moreIchnos Glenmark Innovation Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ichnos Glenmark Innovation your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Ichnos Glenmark Innovation has new funding data
Click to see if Ichnos Glenmark Innovation had a recent Job posting/layoffs
Ichnos Glenmark Innovation, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ichnos Glenmark Innovation is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Ichnos Glenmark Innovation
Product Launch: Get notified when Ichnos Glenmark Innovation launches new products
Earning: See what the market has to say on Ichnos Glenmark Innovation recently announced quarterly report
Check if Ichnos Glenmark Innovation has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Ichnos Glenmark Innovation is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Ichnos Glenmark Innovation is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Ichnos Glenmark Innovation.
Ichnos Glenmark Innovation Tech Stack
A closer look at the technologies used by Ichnos Glenmark Innovation
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Event
Person-Based
Cyril Konto, President, Chief Executive Officer & Director, Board, appeared on a podcast called "Business Of Biotech" on 11/24/2025. Topics discussed include Biotech Collaboration, Multi-Specific Antibodies, Emerging Markets.
Events, Podcast
Open Position
Open Position
Ichnos Glenmark Innovation News & Media
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a 1st-in-Class Multispecific Immune Cells Activator Targeting Solid TumorsIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific AntibodyFull Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
Ichnos Glenmark Innovation presented full results of TRIgnite-1 study of ISB 2001 at ASCO showing continued high response rate and favorable safety profileIchnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
IGI, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ISB 2001.
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Ichnos Glenmark Innovation
Sign Up For FreeTo access detailed company insights
IGI, Inc. is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® techn... Read More
